Arvinas Inc. — VEPPANU (vepdegestrant) - (VERITAC-2) · Breast cancer.
Run-up into the decision (T-120 → T+5)
Daily close, T-120 (11/14/25) through T+5. Run-up high $13.83 on 2/4/26, low $9.82 on 4/29/26 (T-120 to T-1). FDA decision 5/1/26. Historical price action, not a forecast.
Key facts
FDA decision date2026-05-01
OutcomeApproved
Drug / candidateVEPPANU (vepdegestrant) - (VERITAC-2)